Clinical trials: Sars-CoV-2
Covid19
Ligilactobacillus Salivarius MP101 for Elderly in a Nursing Home
The objective of this work was to investigate the effect of Ligilactobacillus salivarius MP101 on the functional (Barthel index), cognitive (GDS/FAST) and nutritional (MNA) status, and on the nasal and fecal inflammatory profiles…
- Trial name
- PROBELDERLY (NCT04922918)
- Testing
- Ligilactobacillus salivarius MP101
- Where
- Spain
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Universidad Complutense de Madrid
SARS-CoV2 Infection
Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine
This is a phase IIb/III, double-blind, randomised, active-controlled, multi-centre, non-inferiority clinical trial that aims to determine safety, tolerability and immunogenicity of a booster vaccination with a recombinant protein…
- Trial name
- NCT06181292
- Testing
- PHH-1V81, Comirnaty Omicron XBB1.5
- Where
- 10 sites in Spain
- Volunteers
- 913 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Smell Dysfunction, Olfactory Disorder
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
Persistent smell loss that can include diminished or distorted smell function is a common symptom of long COVID syndrome. There are limited treatment options for long COVID-related smell loss.
- Conditions
- Smell Dysfunction, Olfactory Disorder, Long COVID
- Trial name
- NCT05855369
- Testing
- Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST)
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- Medical University of South Carolina
COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients
The purpose of the study is to compare the efficacy of anti-COVID-19 immune globulin (human) 20% (C19-IG 20%) (2 doses) versus placebo with regard to the percentage of asymptomatic participants who remain asymptomatic, i.e., who…
- Trial name
- COVID-19 (NCT04847141)
- Testing
- C19-IG 20%, 0.9% Sodium chloride
- Where
- 12 sites in Spain
- Volunteers
- 465 people
- Sponsor
- Grifols Therapeutics LLC
COVID-19
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19
The purpose of this study is to assess the safety and efficacy of merimepodib (MMPD) oral solution when administered in combination with remdesivir in adult patients with advanced COVID-19.
- Trial name
- NCT04410354
- Testing
- Merimepodib, Remdesivir
- Where
- 10 sites in United States
- Volunteers
- 44 people
- Sponsor
- ViralClear Pharmaceuticals, Inc.
Covid19
Medical-biological Research of the Pathogenesis of COVID-19 Disease Caused by SARS-CoV-2
Сonducting in-depth medical and biological studies of the pathogenesis of the disease caused by the SARS-CoV-2 in Moscow, the Moscow region and some other regions of the Russian Federation.
- Trial name
- COV2020 (NCT04611841)
- Where
- Russia
- Volunteers
- 250 people
- Sponsor
- Federal Research and Clinical Center of Physical-Chemical Medicine
COVID - 19, Long COVID Syndrome
Dapagliflozin for Long COVID Syndrome
This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.
- Conditions
- COVID - 19, Long COVID Syndrome, SARS CoV-2
- Trial name
- DALCO (NCT06907251)
- Testing
- Dapagliflozin (DAPA)
- Where
- Canada
- Volunteers
- 192 people
- Sponsor
- Ottawa Heart Institute Research Corporation
COVID-19
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
- Trial name
- NCT04354831
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Medical College of Wisconsin
COVID-19 Pneumonia
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Risk of COVID_19
1. To determine the risk of COVID -19 in patients who use ACEI and ARBS 2. To determine the Effect of ACEI and ARBS on COVID -19 infection . 3. To determine the Severity of COVID -19 in patients who use ACEI and ARBS .
- Trial name
- NCT05398731
- Testing
- Covid_19
- Volunteers
- 400 people
- Sponsor
- Assiut University
SARS-CoV-2, Covid19
National Survey Concerning Vaccination Against COVID-19 in Nursing Homes and Long-Term Care Units
The COVID-19 pandemic is a challenge for the French healthcare system, particularly among the elderly due to their particular vulnerability to the serious consequences of the disease, with an estimated mortality rate of around…
- Trial name
- VACOVID-SENIOR (NCT04779541)
- Testing
- observation
- Where
- France
- Volunteers
- 323 people
- Sponsor
- University Hospital, Angers
Haemoglobinopathies
Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19
The COVID-19 pandemic is causing many deaths around the world, putting a strain on health services. Patients with pre-existing chronic conditions are most affected by the SARS-COV2 infection.
- Trial name
- NCT04746066
- Where
- 2 sites in Italy
- Volunteers
- 10,000 people
- Sponsor
- Società Italiana Talassemie ed Emoglobinopatie
SARS-CoV2 Infection
COVID-19 SARS-CoV-2 RAST Study
The SARS-CoV-2 BioMedomics Rapid Antigen Screening Test (COV-SCAN) is an at-home rapid antigen COVID-19 antigen screening test device.
- Trial name
- NCT06452056
- Testing
- Rapid Antigen Screening Test
- Where
- United States
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Columbia University
COVID-19 Infection
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine, for the prevention of COVID-19 infection.
- Trial name
- NCT04639466
- Testing
- Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
- Where
- 3 sites in United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- GeoVax, Inc.
COVID-19, Vaccine Reaction
Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases
Previous studies should that patients with chronic liver diseases, cirrhosis, hepatocellular carcinoma and post-liver-trasplant status had lower immunological response to SARS-CoV-2 vaccines than healthy population.
- Conditions
- COVID-19, Vaccine Reaction, Liver Diseases
- Trial name
- NMCIDCHESS2201 (NCT05204602)
- Where
- 19 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Huashan Hospital
Long COVID, Long Covid19
Narrative Intervention for Long COVID-19 (NICO)
This T1 proof of concept trial is designed to test the Narrative Intervention for Long COVID-19 intervention.
- Trial name
- NICO (NCT06091293)
- Testing
- Narrative Intervention for Long COVID-19 (NICO)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Colorado, Denver
COVID-19, SARS-CoV2 Infection
Surveillance Among Healthcare Workers for SARS-Coronavirus-2 Infection
This study aims to investigate the epidemiology of SARS-CoV-2 infection among: i) HCW who triage patients with suspected SARS-CoV-2 infection and provide care to COVID-19 patients; and ii) laboratory personnel who test clinical…
- Trial name
- NCT05175963
- Where
- South Africa
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Farzanah Laher
Mucormycosis, Hematologic Malignancies
Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China
The project intends to carry out a retrospective study on the epidemiology, predisposing factors, clinical manifestations, diagnosis, treatment, prognosis and economic burden of mucormycosis in a Chinese single-center allogeneic…
- Conditions
- Mucormycosis, Hematologic Malignancies, COVID-19
- Trial name
- NCT06900114
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Post Covid-19, Hemiplegic
Lung Boost Trainer Versus Incentive Spirometer in Post COVID-19 Hemiplegic CP Children
Cerebral palsy (CP) is the most common physical disability in children. Children with CP have a higher incidence of respiratory dysfunction than healthy children.
- Conditions
- Post Covid-19, Hemiplegic, CP (Cerebral Palsy)
- Trial name
- COVID-19 CP (NCT07508332)
- Testing
- Lung boost trainer (LBT), Incentive Spirometer Training ( IST), Traditional Respiratory Physical Therapy Protocol (TRPT)
- Where
- 5 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
COVID-19
Safety Study of COVID19 Vaccine on the Market
Popular topic:Multi-center safety observation of recombinant Novel Coronavirus protein vaccine (CHO cells) in a large population Study population:People aged 18 and above
- Trial name
- NCT05890521
- Testing
- Recombinant new coronavirus vaccine (CHO cell)
- Where
- China
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19, Influenza
A Study of the GRIP Influenza and SARS-CoV-2 POC Assays
The purpose of this research is to determine if the use of a new device can accurately detect a virus infection.
- Trial name
- NCT05674370
- Testing
- GRIP Electronic Diagnostic Chip, Laboratory-based nucleic acid amplification tests (NAATs)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic